Top Markets
#1 Threshold Network Threshold Network +64.14%
#2 TENDIES TENDIES +60.80%
#3 Cash Cat Cash Cat +19.85%
#4 OSK OSK +15.90%
#5 Falcon Finance Falcon Finance +13.86%
#6 Magma Finance Magma Finance +13.63%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Kite Kite +12.56%
#9 Asteroid Shiba Asteroid Shiba +11.93%
#10 AI Analysis Token AI Analysis Token +8.48%
Coin of the day
Threshold Network Threshold Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Rang in aandelen #17125
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Aandeelprijs
$3.56
Marktkapitalisatie
$257.37M
Verandering (1 dag)
5.26%
Verandering (1 jaar)
38.35%
Land
FR
Handel Cellectis S.A. (ALCLS)

Categorie

Healthcare
Omzet van Cellectis S.A. (ALCLS)
Omzet in Sep 2026 TTM: 0
Volgens de laatste financiële rapporten van Cellectis S.A. bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Cellectis S.A. van 2026 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH